Form 4 for OPRX OptimizeRx Corp
Accepted 2024-12-27 00:00:00 ET · period of report 2024-12-23 · accession 0001628280-24-052485 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-12-27 | 2024-12-23 | OPRX | Besch Doug | Chief Product Off | A - Grant | $0.00 | +41.4K | 53.0K | +357% | $0 |
| D | 2024-12-27 | 2024-12-23 | OPRX | Besch Doug | Chief Product Off | A - Grant | $0.00 | +77.7K | 77.7K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-12-23 | A | A | 41,408 | $0.00 | 52,991 | D | — | — | (F1) Grant of restricted stock units representing a contingent right to receive shares of OptimizeRx common stock. The restricted stock units will vest in three equal annual installments beginning on December 23, 2025, which is the first anniversary of the date of grant. |
| 2 | Derivative | Stock Option | 2024-12-23 | A | A | 77,742 | $0.00 | 77,742 | D | $4.83 · 2025-12-23 to 2027-12-23 | 77,742 Common Stock | (F2) The stock option vests in three equal annual installments beginning December 23, 2025, the first anniversary of the grant date. |